Antithrombotic Therapy After Cardiac Surgery: Role of Different Oral
Anticoagulants
Abstract
Background and aim of the study: Aim of this study is to compare the
incidence of postoperative bleeding events, identified as pericardial
effusion, for those patients undergoing cardiac surgery and discharged
on vitamin K antagonist (VKA) versus those discharged on NOACs. Methods:
This was a retrospective observational cohort study; from July 2017 to
July 2019, all the patients who underwent any cardiac surgical procedure
and discharged on any oral anticoagulant, were rolled in the study. The
study variables and setting followed the STROBE checklist. The final
cohort was constituted by 382 patients (mean age 70±11.2 years);
260(68.1%) patients were discharged on VKA and 122(31.9%) were
discharged on NOACs. The primary end point was the incidence of major
postoperative bleeding, defined as pericardial effusion requiring
surgical re-exploration. The key secondary composite end point was the
late re-admission for pericardial effusion. Results: The overall
incidence of in-hospital immediate bleeding events, with need of
re-exploration for pericardial effusion, was 4.7% (n=18). The incidence
of re-admission for pericardial effusion was 3.1% (n=12). Eight of
those patients had surgical re-exploration: four patients were
discharged on NOACs and the remnant four ones were discharged on VKA. No
significant relationships were observed between the different oral
anticoagulants and the incidence of pericardial effusion, at any time.
No ischemic and thromboembolic events were recorded. Conclusions: The
use of non-vitamin K antagonist oral anticoagulant, in post cardiac
surgery patients, does not increase the incidence of major bleeding
events, intended as immediate or late pericardial effusion.